Heart Metabolics Ltd., of Dublin, received an agreement letter from the FDA related to the company's proposed phase III trial special protocol assessment, agreeing to a single, randomized, pivotal trial of 350 patients evaluating perhexiline for the treatment of moderate-to-severe hypertrophic cardiomyopathy.